Skip to main content
Caplight Logo









Epicrispr Biotechnologies

Epicrispr Biotechnologies

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://epicrispr.com/

Last Round

Series C

Aug 11, 2026

Est. Valuation

$95.14M

Total Funding Raised

$213M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Epicrispr Biotechnologies is a biotechnology company developing gene-modulating therapies using its proprietary Gene Expression Modulation System (GEMS) to treat a range of genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

epigenetic engineeringepigenetic editinggene expression modulationgenetic medicinesCRISPR-based platformCRISPR 2.0gene therapyepigenome editingFSHD therapyrare disease therapygene silencingAAV vector deliveryGEMS platformCasMINIneuromuscular disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Epicrispr Biotechnologies Comparables

Compare Epicrispr Biotechnologies with similar companies based on industry and business-model similarity.

Epicrispr Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tune Therapeutics
84%
Moonwalk Biosciences
84%
Chroma Medicine
83%

Epicrispr Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 11, 2026
Series BMar 26, 2025
Series AJul 12, 2022

Key People

Founding team and executive leadership

Amber Salzman

CEO, CEO

Executive Team

Epicrispr Biotechnologies Investors

Notable investors and investment history

Epicrispr Biotechnologies investors
InvestorRounds
Janus Henderson GroupSeries C
Horizons VenturesSeries A
abrdn Inc.Series C
Ally Bridge GroupSeries B
Readout CapitalSeries C
Cormorant Asset ManagementSeries C
Duquesne Family OfficeSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 11, 2026

    $90M round led by Janus Henderson Group and Octagon Capital Advisors.

  • Jul 27, 2026

    Monthly visitors increased 68% MoM.

Epicrispr Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Epicrispr Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Epicrispr Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range49
Year Founded2018
Last FundingAug 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?